TfRMAb-TNFR treatment decreased the levels of neprilysin (Fig. 3A) and β-secretase (BACE1) (Fig. 3B), proteins involved in amyloid degradation and Aβ processing, respectively, in the 3xTg-AD mice compared with saline treatment. Here, TNFRSF1A is linked to Alzheimer disease.